secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950142-23-001396
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q1 core revenue up 1.8% YoY; operating cash burn cut 55.8% sequentially
--------------------------------------------------------------------------------

- GAAP revenue $25.1M (-5.2% YoY); core product/service revenue $24.3M (+1.8% YoY).
- GAAP product margin 46.6% (+567 bps QoQ); non-GAAP margin 60.9% (+792 bps QoQ).
- Operating cash burn $8.5M, down from $19.2M in Q4 2022 and $15.6M in Q1 2022.
- Launched Hyperion XTi Imaging System; subleased 50% of SSF space; repurchased 1.3M shares for $2.5M.
- FY2023 guidance: flat-to-moderate core revenue growth; GAAP opex $118-123M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/0000950142-23-001396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/eh230357220_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-23-001396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer